These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24662920)

  • 1. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.
    Mohni KN; Kavanaugh GM; Cortez D
    Cancer Res; 2014 May; 74(10):2835-45. PubMed ID: 24662920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
    Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
    Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
    Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
    J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
    Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
    PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
    Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
    Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
    Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
    Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
    Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
    Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
    Sultana R; Abdel-Fatah T; Perry C; Moseley P; Albarakti N; Mohan V; Seedhouse C; Chan S; Madhusudan S
    PLoS One; 2013; 8(2):e57098. PubMed ID: 23451157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
    Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
    Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy.
    Schneider HE; Schmitt LM; Job A; Lankat-Buttgereit B; Gress T; Buchholz M; Gallmeier E
    Neoplasia; 2024 Nov; 57():101038. PubMed ID: 39128273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.
    Touat M; Sourisseau T; Dorvault N; Chabanon RM; Garrido M; Morel D; Krastev DB; Bigot L; Adam J; Frankum JR; Durand S; Pontoizeau C; Souquère S; Kuo MS; Sauvaigo S; Mardakheh F; Sarasin A; Olaussen KA; Friboulet L; Bouillaud F; Pierron G; Ashworth A; Lombès A; Lord CJ; Soria JC; Postel-Vinay S
    J Clin Invest; 2018 Apr; 128(4):1671-1687. PubMed ID: 29447131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
    Wang C; Wang G; Feng X; Shepherd P; Zhang J; Tang M; Chen Z; Srivastava M; McLaughlin ME; Navone NM; Hart GT; Chen J
    Oncogene; 2019 Apr; 38(14):2451-2463. PubMed ID: 30532030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the ATR-DNAPKcs-RB axis drives G1/S-phase transition and sensitizes triple-negative breast cancer (TNBC) to DNA holliday junctions.
    Hu YM; Liu XC; Hu L; Dong ZW; Yao HY; Wang YJ; Zhao WJ; Xiang YK; Liu Y; Wang HB; Yin QK
    Biochem Pharmacol; 2024 Jul; 225():116310. PubMed ID: 38788960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
    Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
    Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.
    Sankunny M; Parikh RA; Lewis DW; Gooding WE; Saunders WS; Gollin SM
    Genes Chromosomes Cancer; 2014 Feb; 53(2):129-43. PubMed ID: 24327542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
    He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
    Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.